Amy Welsh
CIK 1951262 · Chief Commercial Officer · last filed 2024-08-26
Amy Welsh is a Chief Commercial Officer who has filed 3 SEC Form 4 insider transactions across 1 company since 2022.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
1
Total Filings
3
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AGILE THERAPEUTICS INC (AGRX) Delisted | Chief Commercial Officer | 13,500 | $1.51 | $20.4K | $0 | 2 | 2023-06-30 |
Recent Filings
3 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-26 | — | Disp (D) | −13,500 | -$20.5K | |
| 2023-06-30 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | +13,500 | $0 | EDGAR |
| 2022-11-14 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.